<DOC>
	<DOCNO>NCT00990509</DOCNO>
	<brief_summary>The purpose study find effect , good bad , medication Albumin subject experienced type stroke know intracerebral hemorrhage ( ICH ) . An ICH spontaneous bleed brain occurs due fragile blood vessel . This research do currently effective treatment ICH . However , study investigator believe Albumin , medication test study , safe may help improve patient recovery ICH time . Subjects enrol study total 90 day . Following enrollment , subject randomize receive 3 daily injection either Albumin Placebo ( liquid drug ) , receive 3 brain MRI scan ( without contrast ) , describe . All subject monitor continuously 96 hour enrollment ( 5 day ) Georgetown ICU . Blood test clinical evaluation neurological status , consist question subject ' functional ability medical history , occur Georgetown ICU every 24 hour post-enrollment Day 5 . Additionally , subject receive daily chest x-ray , daily EKGs ( exams monitor heart placing electrode , small monitor , skin specific location ) . Similar clinical evaluation occur Day 30 Day 90 . Should subject discharged time point , day 30 assessment occur phone , day 90 assessment occur in-person Georgetown University Medical Center .</brief_summary>
	<brief_title>Albumin Intracerebral Hemorrhage Intervention</brief_title>
	<detailed_description>We aim determine safety explore efficacy human albumin neuroprotective ( cytoprotective ) agent treatment acute primary supratentorial ICH . Albumin therapy show cytoprotective animal study ischemic stroke intracerebral hemorrhage , phase II human study ischemic stroke . To date acute intervention ( beyond supportive medical care ) identify improve outcome patient primary ICH . Neuronal injury primary ICH due space occupy effect hemorrhage also due development edema toxicity blood breakdown product subacute phase . Cytoprotective strategy target limit blood brain barrier ( BBB ) breakdown edema formation hold promise treatment strategy limit injury . A number MR image outcome marker demonstrate potential neuroprotective effect include measure hematoma volume , perihematomal edema , blood brain barrier disruption . The term `` hyperintense acute injury marker '' ( HARM ) propose describe radiologic find hyperintense signal within cerebrospinal fluid space visualize post-contrast fluid attenuate inversion recovery ( FLAIR ) MRI patient acute ischemic stroke . HARM potential serve marker blood brain barrier disruption patient primary ICH . The current study involve serial MR image ICH patient randomize placebo vs. albumin ass whether difference frequency HARM perihematomal edema albumin treat patient .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<criteria>Primary supratentorial ICH &lt; 48 hour symptom onset Age &gt; 18 Signed inform consent obtain patient patient 's legally authorize representative ICH volume &lt; 5 cc Glasgow Coma Scale &lt; 6 Surgical evacuation anticipate Preexisting medical , neurological psychiatric disease would confound neurological , functional , imaging evaluation Pregnancy breastfeed Hemodynamic instability ( SBP &lt; 100 mmHg , &gt; 200 mmHg ) Current participation another experimental treatment protocol Renal impairment GFR &lt; 30 Creatinine &gt; 2.0 History know allergy albumin History know severe allergy rubber latex Episode/exacerbation congestive heart failure ( CHF ) cause last 6 month . ( An episode congestive heart failure heart failure require change medication , diet hospitalization ) Acute myocardial infarction last 6 month Elevated serum troponin level admission &gt; 0.1 mcg/L Known valvular heart disease CHF last 6 month Known ( investigator 's judgment ) existence severe aortic stenosis mitral stenosis Cardiac surgery involve thoracotomy ( e.g. , coronary artery bypass graft ( CABG ) , valve replacement surgery ) last 6 month Suspicion aortic dissection admission Acute arrhythmia ( include tachy bradycardia ) hemodynamic instability admission ( systolic blood pressure &lt; 100 mmHg ) . Findings physical examination following : ( 1 ) jugular venous distention ( JVP &gt; 4 cm sternal angle ) ; ( 2 ) 3rd heart sound ; ( 3 ) rest tachycardia ( heart rate &gt; 100/min ) attributable congestive heart failure ; ( 4 ) abnormal hepatojugular reflux ; ( 5 ) low extremity pit edema attributable congestive heart failure without apparent cause ; ( 6 ) bilateral rale ; and/or ( 7 ) chest xray perform , definite evidence pulmonary edema , bilateral pleural effusion , pulmonary vascular redistribution . Current acute chronic lung disease require supplemental chronic intermittent oxygen therapy . Prosthetic heart valves Contraindication MRI ( metal implant , etc . ) Documented left ventricular ejection fraction &lt; 35 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Primary ICH</keyword>
	<keyword>Albumin</keyword>
	<keyword>MRI</keyword>
	<keyword>Neuroimaging outcome</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Phase II</keyword>
	<keyword>Blinded</keyword>
	<keyword>Safety</keyword>
	<keyword>Acute ICH</keyword>
	<keyword>ICH</keyword>
	<keyword>Primary acute ( &lt; 48 hour ) supratentorial ICH</keyword>
</DOC>